Clinical Research Directory
Browse clinical research sites, groups, and studies.
36 clinical studies listed.
Filters:
Tundra lists 36 Cannabis clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07603518
The Pharmacokinetics of a Hemp-Based Topical Product
This study will evaluate the pharmacokinetic effects of acute and chronic dosing of a hemp-based cannabidiol (CBD) topical lotion with low levels of delta-9-tetrahydrocannabinol (THC) in a sanitized and controlled environment.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2026-09-03
1 state
NCT05563948
Repeated Administration of Cannabis Varying in THC and CBD
The majority of the \>3 million medical cannabis patients in the U.S. use cannabis products to manage pain but many questions remain. This project is designed to answer three questions that will fill important voids in the field's understanding of sustained cannabis use: 1) is abrupt cessation of cannabis associated with increased pain sensitivity; 2) does tolerance develop to the analgesic and abuse-related effects of repeatedly administered cannabis with varying ratios of THC and CBD, and is this tolerance reversible following a period of abstinence; 3) how does repeated cannabis use affect levels of endocannabinoids, and are these changes associated with changes in pain sensitivity and abuse liability? In this study, the investigators will enroll participants (N=100 healthy, cannabis-using men and non-pregnant women, ages 21-65) inpatient for 15 days. They will be randomized to one of four cannabis conditions (n=25/group). Following a day of standardization on which participants will receive their assigned cannabis condition (Day 1), cannabis will be administered repeatedly for 14 days (Day 2-15). The investigators will measure abuse-related effects ("Good Drug Effect"), endocannabinoid levels and two distinct types of experimental pain: The Cold Pressor Test and Quantitative Sensory Testing Thermal Temporal Summation. Given the widespread use of cannabis for pain, understanding the consequences of daily repeated administration of cannabis with THC:CBD ratios that are representative of most medical cannabis products on pain, abuse liability, and endocannabinoids is imperative.
Gender: All
Ages: 21 Years - 65 Years
Updated: 2026-09-01
1 state
NCT06473701
Reducing Breathlessness With Dronabinol in COPD Patients
This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).
Gender: All
Ages: 18 Years - Any
Updated: 2026-08-28
1 state
NCT05160688
Changes in Cognition and Psychiatric Disorder Symptoms During Cannabis Abstinence Using a Novel Discordant Twin Design
This study will test whether 42 days of cannabis abstinence, compared to continued cannabis use, is associated with improvements in cognition and psychiatric disorder symptoms. Identical twins, who are concordant on cannabis use, will be experimentally-manipulated to be discordant for 42 days. Each twin, within a twin pair, will be randomly assigned to either the contingency management condition, incentive-based protocol to promote cannabis abstinence, or control condition, no changes in cannabis use requested.
Gender: All
Ages: 31 Years - 47 Years
Updated: 2026-08-20
1 state
NCT05528380
Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use
This study will recruit 20 women who are high risk for prenatal cannabis use for a 12-week program of using the tracker and receiving a Lifestyle Physical Activity program. The primary outcomes will be self reported percent days of cannabis use and physical activity. Secondary outcomes include self -reported measures of depression and anxiety symptoms, adaptive coping, and self-efficacy for cannabis abstinence.
Gender: FEMALE
Ages: 18 Years - Any
Updated: 2026-08-13
1 state
NCT07434895
Repeated CBD Administration and Cannabis Outcomes
This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2026-08-12
1 state
NCT05351905
Improving Pain Disability With the Use of Oral Cannabinoids
The investigators are conducting a pilot (i.e. a small study) in order to find out the effectiveness and safety of medical cannabis in the management of chronic pain. At the end of this 3 month study, investigators will gather information on how easy it is for patients to enroll and complete the entire study. The results of this pilot study will help the study team design a larger randomized controlled trial.
Gender: All
Ages: 25 Years - Any
Updated: 2026-07-22
1 state
NCT06218550
Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance
Delta-8-THC is an isomer of delta-9-THC that has become widely available due to the legalization of hemp and its derivatives. Very little controlled research has been conducted with delta-8-THC and some research suggests it produces similar effects to delta-9-THC, albeit at lower potency. The present study will evaluate the dose effects of delta-8-THC, compared with delta-9-THC, on simulated driving performance, field sobriety tests, cognitive performance, and biomarkers of exposure to cannabinoids. The results will inform policy and education related to impairment due to acute delta-8-THC exposure via vaporization and oral ingestion.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2026-07-20
1 state
NCT07652853
Allergenic Risk Assessment of Hemp Seed
Cannabis sativa is an annual herbaceous plant from the Cannabaceae family that has been cultivated and consumed by humans for thousands of years. Its main uses include fiber production, seeds for human and animal food, and psychoactive medications. Indeed, cannabis is the most commonly consumed illicit substance among adolescents and poses a major public health issue. Allergic risks associated with cannabis have already been documented. At the same time, the consumption of hemp seeds is increasing due to the current agro-food context and the rise of vegan and vegetarian diets. This new food raises questions about its potential allergic risks, especially since the prevalence and severity of food allergies have been steadily increasing over the years. In this context, cases of anaphylaxis related to hemp seeds have already been reported. However, the potential allergic risk associated with hemp seeds remains largely unstudied to date. Several reasons make research into hemp seed allergies relevant: i) increased exposure to Cannabis sativa in its various forms, with the possibility of finding identical or similar proteins in the seeds; ii) changes in dietary habits, with the vegan trend encouraging the consumption of many seeds, including hemp seeds.
Gender: All
Ages: 2 Years - Any
Updated: 2026-06-17
NCT06919276
Nicotine and Cannabis Vape Labeling Experiment - Spring 2025
This study assesses how the ways in which nicotine and cannabis vaping devices are labeled impact use susceptibility, anticipated effects, and health harm.
Gender: All
Ages: 11 Years - 19 Years
Updated: 2026-05-22
1 state
NCT06669585
Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3
This study investigates the impact of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on recognition memory in healthy, regular cannabis users. Participants complete the same recognition memory task after self-administering one of two different strains of cannabis flower one day and while not intoxicated another day. Event-related potentials (ERPs) are measured via electroencephalogram (EEG) during the recognition memory task. Blood is collected to quantify THC and CBD exposure. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.
Gender: All
Ages: 21 Years - 40 Years
Updated: 2026-05-12
1 state
NCT06120855
Study on Regulated Cannabis Sales in Pharmacies
Though regulated cannabis sales are increasing, little is known about the individual health effects of cannabis regulation. Data from countries with a regulated market can be used to test the effect of regulation on the price of cannabis in the illicit market, and to explore its effect on social and health outcomes at the societal level, but strength of evidence for individual health and social outcomes is more limited because it must be aggregated on a state or country level. Data on individual and social outcomes should include baseline measurements before and outcome measurements after regulations changed. In this context, randomized-controlled trials are the least biased source of data on the effects of interventions. The SCRIPT study aims to investigate the individual health and social impact on recreational cannabis users who are allowed to purchase authorized, regulated cannabis from Swiss pharmacies compared to users who buy cannabis on the illicit market. Participants are randomly allocated in one of the two groups and followed-up for 6 months. After 6 months, all participants are allowed to participate in the intervention and the cohort is followed up for another 18 months. The intervention includes various offers: Participants can choose between cannabis sorts and delivery methods, and they are encouraged to shift from smoking cannabis to vaping cannabis-containing e-liquids, vaporizing cannabis blossoms or using oral cannabis. Vaping / vaporizing electronic devices are also recommended. At the same time, pharmacists offer opportunistic smoking cessation and problematic cannabis, alcohol use and further drug use counseling that conforms to motivational interviewing principles. The SCRIPT study adheres to rigorous quality criteria for the production and storage of regulated cannabis products. Only vaping / vaporizing electronic devices which are validated to reduce exposure to toxicants compared to cannabis smoking are recommended.
Gender: All
Ages: 18 Years - Any
Updated: 2026-05-11
NCT05629702
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide (TMZ).
Gender: All
Ages: 16 Years - Any
Updated: 2026-05-05
2 states
NCT05514899
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures designed to monitor subject safety and measure the effects of the study drug.
Gender: All
Ages: 21 Years - 70 Years
Updated: 2026-05-01
1 state
NCT02404688
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Gender: All
Ages: 21 Years - 55 Years
Updated: 2026-04-29
1 state
NCT02709954
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Gender: All
Ages: 21 Years - 55 Years
Updated: 2026-04-29
1 state
NCT02710097
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Gender: All
Ages: 21 Years - 55 Years
Updated: 2026-04-29
1 state
NCT02407808
Cannabinoids, Learning, and Memory
The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2026-04-29
1 state
NCT04704271
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2026-04-29
1 state
NCT02710331
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Gender: All
Ages: 21 Years - 55 Years
Updated: 2026-04-27
1 state
NCT04810858
Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury
This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.
Gender: All
Ages: 25 Years - 59 Years
Updated: 2026-03-31
1 state
NCT04325958
Age Differences in the Effects of Cannabis on Simulated Driving
Epidemiological studies suggest that the use of cannabis is associated with an increase in the risk of motor vehicle collisions. It is also known that younger users may be at increased risk for motor vehicle collisions. Further, the frequency with which cannabis is used may be an important variable in determining the effects of cannabis on driving. The purpose of the present study will be to investigate the effects of cannabis on simulated driving in young as compared to middle-aged drivers. Half of the participants will be occasional users of cannabis and half will be frequent users of cannabis.
Gender: All
Ages: 19 Years - 45 Years
Updated: 2026-03-23
1 state
NCT07417059
Sex Hormones Impact on Cannabis Response
The goal of this study is to systematically determine whether the cannabis response in human females is related to SH fluctuations throughout the menstrual cycle.
Gender: FEMALE
Ages: 18 Years - 40 Years
Updated: 2026-02-18
NCT05999383
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.
Gender: All
Ages: 21 Years - 65 Years
Updated: 2026-01-07
1 state